Phosphoinositide polyphosphates (PIPns) are biosynthesized via the interplay of phosphatases and kinases and constitute key signaling molecules in cellular communication. The isolation, identification, and characterization of proteins that bind and metabolize PIPns have been realized using chemically-synthesized affinity probes, including photoaffinity labels, solid-support immobilized ligands, biotinylated probes, antigenic ligands, and fluorescently-labeled probes. We propose to expand the repertoire and uses of PIPE affinity probes by developing molecular sensors for intracellular events in the phosphoinositide signaling pathway. Thus, we will address six areas: (i) synthesis of affinity probes for PIPn-binding domain (PIPnBD) studies; (ii) optimization of cell permeant PIPns, (iii) development of novel fluorescence and antibody- based assays for measuring PIPn kinase and phosphatase activity (iv) discovery of new PIPn-binding proteins using classical biochemistry and in vitro expression cloning, (v) use of peptide libraries to identify novel peptides that act as PIPn selective mimics, and (vi) selected biophysical studies of novel PIPnBD-PIPn complexes. At The University of Utah, we will focus on preparation of affinity probes, development of assays, and biophysical study of selected complexes. At Utah State University, we will explore uses of antibody and affinity probes in cell biology and protein discovery. With collaborators elsewhere, new PIPn binding proteins will be identified and characterized, and uses of unique reagents will be developed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS029632-12
Application #
6539721
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
1992-04-01
Project End
2004-02-28
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
12
Fiscal Year
2002
Total Cost
$274,322
Indirect Cost
Name
University of Utah
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Murph, Mandi M; Jiang, Guowei W; Altman, Molly K et al. (2015) Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma. Bioorg Med Chem 23:5999-6013
Jiang, Guowei; Madan, Damian; Prestwich, Glenn D (2011) Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin. Bioorg Med Chem Lett 21:5098-101
He, Ju; Gajewiak, Joanna; Scott, Jordan L et al. (2011) Metabolically stabilized derivatives of phosphatidylinositol 4-phosphate: synthesis and applications. Chem Biol 18:1312-9
Inoue, Asuka; Arima, Naoaki; Ishiguro, Jun et al. (2011) LPA-producing enzyme PA-PLA?? regulates hair follicle development by modulating EGFR signalling. EMBO J 30:4248-60
Zhang, Honglu; He, Ju; Kutateladze, Tatiana G et al. (2010) 5-Stabilized phosphatidylinositol 3,4,5-trisphosphate analogues bind Grp1 PH, inhibit phosphoinositide phosphatases, and block neutrophil migration. Chembiochem 11:388-95
Best, Michael D; Zhang, Honglu; Prestwich, Glenn D (2010) Inositol polyphosphates, diphosphoinositol polyphosphates and phosphatidylinositol polyphosphate lipids: structure, synthesis, and development of probes for studying biological activity. Nat Prod Rep 27:1403-30
Xu, Xiaoyu; Prestwich, Glenn D (2010) Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 116:1739-50
Altman, Molly K; Gopal, Vashisht; Jia, Wei et al. (2010) Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer 9:140
Morrison, B H; Haney, R; Lamarre, E et al. (2009) Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma. Oncogene 28:2383-92
Xu, Xiaoyu; Yang, Guanghui; Zhang, Honglu et al. (2009) Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Prostaglandins Other Lipid Mediat 89:140-6

Showing the most recent 10 out of 108 publications